Leading Global Pharmaceutical Company, Teva Pharmaceutical Industries, Transfers Stock Listing to the New York Stock Exchange from NASDAQ<p>
“Teva is a global pharmaceutical company and a leader in their industry with a dedication to their patients,” said Diederik Zandstra, Head of International Listings, NYSE Euronext. “We are proud that Teva has chosen to transfer to the NYSE and recognizes the value of our global community, market structure and technology. We look forward to our partnership with Teva and its shareholders."
Dr. Phillip Frost, Chairman of the Board of Directors and President and CEO Dr. Jeremy M. Levin, along with members of Teva Pharmaceutical’s management team and employees from around the globe, ring the NYSE Opening Bell to commemorate Teva’s transfer of its stock listing to the NYSE from NASDAQ.
Dr. Phillip Frost, Chairman of the Board of Directors and President and CEO Dr. Jeremy M. Levin pose with the NYSE façade banner welcoming Teva Pharmaceutical to the New York Stock Exchange on its first day as NYSE-listed company.
Teva Pharmaceuticalis the second largest company to transfer its stock listing to the NYSE from NASDAQ. Teva is the seventh company to transfer from NASDAQ to the NYSE in 2012 following Hercules Technology Growth Capital Inc. (NYSE: HTGC – 4/30/12); TD Ameritrade Holding Company (NYSE: AMTD – 4/25/12); Arabian American Development Co. (NYSE: ARSD – 4/2); Halcon Resources Corp (NYSE: HK – 3/26); Kaman Corporation (NYSE: KAMN – 2/7) and Team Inc. (NYSE: TISI – 1/3).
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011. (Source: Teva Pharmaceutical Industries Ltd.)
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
